Martin Meeson’s first task as incoming CEO at FUJIFILM Diosynth Biotechnologies was to send everyone home, and it’s been a sprint ever since.

That was nearly two years ago as the pandemic hit. Overnight, the CDMO leader had to invent new ways of orchestrating their essential formulation and manufacturing supply chains. Facing a surge of demand from biotechs entering the clinic, the company also invested big in new facilities and technologies.

“Advancing tomorrow’s medicines” is on the wall at FUJIFILM Diosynth, Meeson told Arsalan Arif, Publisher of Endpoints News, at a #JPM22 fireside chat. They discussed the philosophy behind that, their outlook for 2022, and how Meeson and his team is looking to shift the paradigm of manufacturing in biopharma.

Click here to read the full article